SEC Filing Analysis: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: An executive at Teva has filed a notice of intent to sell approximately $700K worth of stock under a pre-scheduled 10b5-1 trading plan.
• Market Impact: The transaction is negligible relative to the company's market capitalization and is not expected to have any market impact.

Company Information

Field	Value
Company	TEVA PHARMACEUTICAL INDUSTRIES LTD
Ticker Symbol	TEVA
CIK	0000818686
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Fox Christine
CIK	0001998173
Title/Position	EVP HEAD OF US COMMERCIAL
Relationship	Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025/11/20 (Approximate)
Transaction Code	S (Proposed Sale)
Security Type	ORDINARY SHARES
Shares Involved	28,229
Price Per Share	~$24.78
Total Value	$699,523.09
Shares Owned After	Not Disclosed
Ownership Type	Not Disclosed

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$699,523.09
% of Market Cap	0.0024%
Shares Transacted	28,229
% of Shares Outstanding	0.0025%
Post-Transaction Ownership	Not Disclosed
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: As a large-cap company with a market capitalization of $29.15 billion, this transaction of approximately $700K is considered routine and immaterial.
• Transaction Significance: The sale represents a tiny fraction of both the market cap and public float, indicating it is not a significant event for the company or its stock.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is of low monetary value relative to the company's size and was executed under a 10b5-1 plan, which decouples the sale from any immediate insider sentiment.

Volume & Sentiment

• Expected Volume Impact: None. The number of shares is too small to impact trading volume.
• Sentiment Indicator: Neutral. Pre-planned sales by executives are common for liquidity and diversification and do not typically influence market sentiment.

Additional Context

Special Circumstances

• The filing explicitly notes the sale is pursuant to a 10b5-1 trading plan adopted on August 11, 2025. This provides an affirmative defense against accusations of trading on non-public information.